PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy
PROSTest demonstrates improved stratification value relative to PSA and could significantly reduce PSA-driven false positive biopsies. Out of 259 non-PCa subjects biopsied based on high PSA levels, applying PROSTest could potentially eliminate 227 biopsies (87.6%). PROSTest superior NPV was not confounded as a tradeoff for the PPV as PROSTest exhibited a sensitivity of ~95% (675/711 PCa detected).
Authors
- Mark Kidd (ORCID: https://orcid.org/0000-0002-1525-5167)
- R. David Rosin
- Kambiz Rahbar (ORCID: https://orcid.org/0000-0002-4591-4055)
- Oliver A. Sartor (ORCID: https://orcid.org/0000-0002-8777-7343)
- Abdel Halim
Institutions
- Tulane University (US)
- German Cancer Research Center (DE)
- University Hospital Münster (DE)
- West Cancer Center (US)
- Wren Laboratories (United States) (US)
- University of the West Indies (BB)
Publication Details
- Journal
- The Prostate
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1002/pros.70052
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00